The clinical positioning of telavancin in Europe

International Journal of Antimicrobial Agents

Volumn 45, Issue 3, 2015, Pages 213-220

  Masterton, Robert ^a   Cornaglia, Giuseppe ^b   Courvalin, Patrice ^c   Lode, Hartmut M ^d   Rello, Jordi ^e   Torres, Antoni ^f  

^a UNIVERSITY OF THE WEST OF SCOTLAND   (United Kingdom)

^b UNIVERSITY OF VERONA   (Italy)

^c INSTITUT PASTEUR   (France)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^f UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Gram positive infections; Hospital acquired pneumonia; MRSA; Nosocomial pneumonia; Telavancin

Indexed keywords

TELAVANCIN; VANCOMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; BIOFILM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG INDICATION; DRUG METABOLISM; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; ENTEROCOCCUS; EUROPE; GRAM POSITIVE INFECTION; HISTORY; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NEPHROTOXICITY; NONHUMAN; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS; CROSS INFECTION; DRUG EFFECTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GRAM POSITIVE BACTERIUM; GRAM-POSITIVE BACTERIAL INFECTIONS; MICROBIOLOGY;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; EUROPE; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 84923696270     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.12.006     Document Type: Review

References (75)

1. European Medicines Agency EPAR summary for the public. Vibativ, telavancin June 2011 European Medicines Agency http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Summary-for-the-public/human/001240/WC500115429.pdf [accessed 6 May 2014]
2. M.R. Leadbetter, S.M. Adams, B. Bazzini, P.R. Fatheree, D.E. Karr, and K.M. Krause Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424) J Antibiot (Tokyo) 57 2004 326 336
3. K.D. Leuthner, C.M. Cheung, and M.J. Rybak Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus J Antimicrob Chemother 58 2006 338 343
4. D.L. Higgins, R. Chang, D.V. Debabov, J. Leung, T. Wu, and K.M. Krause Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus Antimicrob Agents Chemother 49 2005 1127 1134
5. S.S. Hegde, N. Reyes, T. Wiens, N. Vanasse, R. Skinner, and J. McCullough Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria Antimicrob Agents Chemother 48 2004 3043 3050
6. A.G. Madrigal, L. Basuino, and H.F. Chambers Efficacy of telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus Antimicrob Agents Chemother 49 2005 3163 3165
7. J.P. Shaw, J. Seroogy, K. Kaniga, D.L. Higgins, M. Kitt, and S. Barriere Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects Antimicrob Agents Chemother 49 2005 195 201
8. K. Duchin, J. Shaw, E. Spencer, J. Seroogy, S. Barriere, and D. Wilbraham Single dose pharmacokinetics (PK) of telavancin in healthy elderly subjects 14th European congress of clinical microbiology and infectious diseases (ECCMID) 1-4 May 2004, Prague, Czech Republic: European Society of Clinical Microbiology and Infectious Diseases 2004 [abstract P1028]
9. S.L.I. Wong, J.P. Shaw, S. Barriere, M. Kitt, and M. Goldberg Pharmacokinetics of intravenous telavancin in subjects with hepatic impairment 46th interscience conference on antimicrobial agents and chemotherapy (ICAAC) 27-30 September 2006, San Francisco, CA., Washington, DC: American Society for Microbiology 2006 [abstract A-1951]
10. M.E. Stryjewski, W.D. O'Riordan, W.K. Lau, F.D. Pien, L.M. Dunbar, and M. Vallee Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to Gram-positive bacteria Clin Infect Dis 40 2005 1601 1607
11. M.E. Stryjewski, V.H. Chu, W.D. O'Riordan, B.L. Warren, L.M. Dunbar, and D.M. Young Telavancin versus standard therapy for the treatment of complicated skin and skin structure infections caused by Gram positive bacteria: FAST 2 Study Antimicrob Agents Chemother 3 2006 862 867
12. M.E. Stryjewski, D.R. Graham, S.E. Wilson, W. O'Riordan, D. Young, and A. Lentnek Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms Clin Infect Dis 46 2008 1683 1693
13. E. Rubinstein, T. Lalani, G.R. Corey, Z.A. Kanafani, E.C. Nannini, and M.G. Rocha Telavancin versus vancomycin for hospital-acquired pneumonia due to Gram-positive pathogens Clin Infect Dis 52 2011 31 40
14. European Medicines Agency Questions and answers on shortcomings in quality assurance at Ben Venue Laboratories. Interim recommendations for centrally authorised medicines December 2011 European Medicines Agency http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2011/12/WC500118986.pdf [accessed 6 May 2014]
15. European Medicines Agency Vibativ. Procedural steps taken and scientific information after the authorisation March 2014 European Medicines Agency http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Procedural-steps-taken-and-scientific-information-after-authorisation/human/001240/WC500131171.pdf [accessed 6 May 2014]
16. ® (telavancin) March 2014 London Stock Exchange http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=11895627 [accessed 6 May 2014]
17. National Institute for Health and Care Excellence Evidence summary: new medicine. Hospital-acquired pneumonia caused by methicillin-resistant Staphylococcus aureus: telavancin July 2014 National Institute for Health and Care Excellence http://www.nice.org.uk/advice/esnm44#summary [accessed 25 July 2014]
18. US Food and Drug Administration FDA approved drug products. Drug details: Vibativ September 2009 US Food and Drug Administration http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails [accessed 25 July 2014]
19. Canadian Antimicrobial Resistance Alliance. Telavancin. http://www.can-r.com/mediaResources/About%20Telavancin.pdf [accessed 6 May 2014].
20. US Food and Drug Administration FDA news release: FDA approves Vibativ for hospitalized patients with bacterial pneumonia June 2013 US Food and Drug Administration http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm358209.htm [accessed 6 May 2014]
21. Telavancin summary of product characteristics (EU). First issued 2 September 2011. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/001240/WC500115364.pdf [accessed 8 May 2014].
22. Astellas Pharma Inc. News release. Astellas announces the withdrawal of EU MAA application for telavancin for complicated skin and soft tissue infections October 2008 Astellas Pharma Inc. http://www.astellas.com/en/corporate/news/pdf/081024-eg.pdf [accessed 12 May 2014]
23. Telavancin prescribing information (US). Revised June 2013. http://www.vibativ.com/docs/VIBATIV-PI-Final.pdf [accessed 8 May 2014]
24. A. King, I. Phillips, and K. Kaniga Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria J Antimicrob Chemother 53 2004 797 803
25. D.C. Draghi, B.M. Benton, M.E. Jones, K.M. Krause, C. Thornsberry, and D.F. Sahm Baseline antistaphylococcal profile of telavancin: results of the 2004-2005 U.S. Surveillance Initiative 46th interscience conference on antimicrobial agents and chemotherapy (ICAAC) 27-30 September 2006, San Francisco, CA., Washington, DC: American Society for Microbiology 2006 [abstract E-0715]
26. D.C. Draghi, B.M. Benton, M.E. Jones, K.M. Krause, C. Thornsberry, and D.F. Sahm In vitro activity of telavancin against enterococci: results from the 2004-2005 U.S. Surveillance Initiative 46th interscience conference on antimicrobial agents and chemotherapy (ICAAC) 27-30 September 2006, San Francisco, CA., Washington, DC: American Society for Microbiology 2006 [abstract E-0717]
27. L.D. Saravolatz, J. Pawlak, and L.B. Johnson Comparative activity of telavancin against isolates of community-associated methicillin-resistant Staphylococcus aureus J Antimicrob Chemother 60 2007 406 409
28. C. Thornsberry, D.C. Draghi, B.M. Benton, M.E. Jones, K.M. Krause, and D.F. Sahm Baseline profile of telavancin activity against streptococci: results of the 2004-2005 U.S. Surveillance Initiative 46th interscience conference on antimicrobial agents and chemotherapy (ICAAC) 27-30 September 2006, San Francisco, CA., Washington, DC: American Society for Microbiology 2006 [abstract E-0719]
29. E.J.C. Goldstein, D.M. Citron, C.V. Merriam, Y.A. Warren, K.L. Tyrrell, and H.T. Fernandez In vitro activities of the new semisynthetic glycopeptide telavancin (TD-6424), vancomycin, daptomycin, linezolid, and four comparator agents against anaerobic Gram-positive species and Corynebacterium spp. Antimicrob Agents Chemother 48 2004 2149 2152
30. S.M. Finegold, M. Bolanos, P. Summanen, and D.R. Molitoris In vitro activity of telavancin and six comparator agents against 460 anaerobic bacteria 45th interscience conference on antimicrobial agents and chemotherapy (ICAAC) 16-19 December 2005, Washington, DC., Washington, DC: American Society for Microbiology 2005 [abstract E-1750]
31. G.G. Zhanel, D. Calic, F. Schweizer, S. Zelenitsky, H. Adam, and P.R. Lagacé-Wiens New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin Drugs 70 2010 859 886
32. C.S. Lunde, S.R. Hartouni, J.W. Janc, M. Mammen, P.P. Humphrey, and B.M. Benton Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II Antimicrob Agents Chemother 53 2009 3375 3383
33. S.N. Leonard, and M.J. Rybak Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious Gram-positive infections Pharmacotherapy 28 2008 458 468
34. J.L. Pace, K. Krause, D. Johnston, D. Debabov, T. Wu, and L. Farrington In vitro activity of TD-6424 against Staphylococcus aureus Antimicrob Agents Chemother 47 2003 3602 3604
35. Y. Keynan, and E. Rubinstein Telavancin in the treatment of invasive Gram-positive infections Clin Audit 4 2012 25 29
36. L. Jafari Saraf, and S.E. Wilson Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections Infect Drug Resist 4 2011 87 95
37. I. Odenholt, E. Lowdin, and O. Cars The pharmacodynamic effects of telavancin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus in the presence of human albumin or serum, and in an in vitro kinetic model Antimicrob Agents Chemother 51 2007 3311 3316
38. K. Kosowska-Shick, C. Clark, G.A. Pankuch, P. McGhee, B. Dewasse, and L. Beachel Activity of telavancin against staphylococci and enterococci determined by MIC and resistance selection studies Antimicrob Agents Chemother 53 2009 4217 4224
39. I.Y. Lubenko, E.V. Strukova, M.V. Smirnova, S.N. Vostrov, Y.A. Portnoy, and S.H. Zinner Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model J Antimicrob Chemother 62 2008 1065 1069
40. C.M. Rubino, S.A. Van Wart, S.M. Bhavnani, P.G. Ambrose, J.S. McCollam, and A. Forrest Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia Antimicrob Agents Chemother 53 2009 4422 4428
41. F.F. Arhin, I. Sarmiento, A. Belley, G.A. McKay, D.C. Draghi, and P. Grover Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing Antimicrob Agents Chemother 52 2008 1597 1603
42. R. Hope, A. Chaudhry, R. Adkin, and D.M. Livermore In vitro activity of telavancin and comparators against selected groups of Gram-positive cocci Int J Antimicrob Agents 41 2013 213 217
43. US Food and Drug Administration (FDA) Highlights of prescribing information 2014 US Food and Drug Administration (FDA) Revised February 2014 http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/022110s007lbl.pdf [accessed 2 June 2014]
44. US National Library of Medicine VIBATIV (telavancin hydrochloride) injection, powder, lyophilized, for solution (Theravance, Inc.). Highlights of prescribing information 2014 US National Library of Medicine Revised March 2014 http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=9fc67b76-9ba1-45ec-9749-ca3f3a6477d9 [accessed 2 June 2014]
45. R.E. Mendes, H.S. Sader, R.K. Flamm, and R.N. Jones Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013) when using a revised susceptibility testing method 24th European congress of clinical microbiology and infectious diseases (ECCMID) 10-13 May 2014, Barcelona, Spain: European Society of Clinical Microbiology and Infectious Diseases 2014 [abstract eP201]
46. S.M. Finegold, M. Bolanos, P.H. Sumannen, and D.R. Molitoris In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates Antimicrob Agents Chemother 53 2009 3996 4001
47. M.A. Pfaller, R.E. Mendes, H.S. Sader, and R.N. Jones Telavancin activity against Gram-positive bacteria isolated from respiratory tract specimens of patients with nosocomial pneumonia J Antimicrob Chemother 65 2010 2396 2404
48. W.T. Jansen, A. Verel, J. Verhoef, and D. Milatovic In vitro activity of telavancin against Gram-positive clinical isolates recently obtained in Europe Antimicrob Agents Chemother 51 2007 3420 3424
49. R.E. Mendes, H.S. Sader, D.J. Farrell, and R.N. Jones Worldwide appraisal and update (2010) of telavancin activity tested against a collection of Gram-positive clinical pathogens from five continents Antimicrob Agents Chemother 56 2012 3999 4004
50. R.E. Mendes, G.J. Moet, M.J. Janechek, and R.N. Jones In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates Antimicrob Agents Chemother 54 2010 2704 2706
51. L.D. Saravolatz, J. Pawlak, and L.B. Johnson In vitro susceptibilities and molecular analysis of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus isolates Clin Infect Dis 55 2012 582 586
52. S. Gander, A. Kinnaird, and R. Finch Telavancin: in vitro activity against staphylococci in a biofilm model J Antimicrob Chemother 56 2005 337 343
53. K.L. LaPlante, and L.A. Mermel In vitro activities of telavancin and vancomycin against biofilm-producing Staphylococcus aureus, S. epidermidis, and Enterococcus faecalis strains Antimicrob Agents Chemother 53 2009 3166 3169
54. K. Smith, C.G. Gemmell, and S. Lang Telavancin shows superior activity to vancomycin with multidrug-resistant Staphylococcus aureus in a range of in vitro biofilm models Eur J Clin Microbiol Infect Dis 32 2013 1327 1332
55. E. Rubinstein, S. Cammarata, T. Oliphant, R. Wunderink Linezolid Nosocomial Pneumonia Study Group Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study Clin Infect Dis 32 2001 402 412
56. R.G. Wunderink, S.K. Cammarata, T.H. Oliphant, M.H. Kollef Linezolid Nosocomial Pneumonia Study Group Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia Clin Ther 25 2003 980 992
57. R.G. Wunderink, J. Rello, S.K. Cammarata, R.V. Croos-Dabrera, and M.H. Kollef Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia Chest 124 2003 1789 1797
58. R.G. Wunderink, M.S. Niederman, M.H. Kollef, A.F. Shorr, M.J. Kunkel, and A. Baruch Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study Clin Infect Dis 54 2012 621 629
59. A. Torres, E. Rubinstein, G.R. Corey, M.E. Stryjewski, and S.L. Barriere Analysis of phase 3 telavancin nosocomial pneumonia data excluding patients with severe renal impairment and acute renal failure J Antimicrob Chemother 69 2014 1119 1126
60. L.J. Scott Telavancin: a review of its use in patients with nosocomial pneumonia Drugs 73 2013 1829 1839
61. 14C]telavancin following intravenous administration to healthy male volunteers Antimicrob Agents Chemother 54 2010 3365 3371
62. K.A. Polyzos, M.N. Mavros, K.Z. Vardakas, M.C. Makris, P.I. Rafailidis, and M.E. Falagas Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis PLoS One 7 2012 e41870
63. S.L. Barriere The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia Future Microbiol 9 2014 281 289
64. Clinigen Specialty Pharmaceuticals. Direct Healthcare Professional Communication on the launch of Vibativ® (telavancin): recommendations for use and important risks (nephrotoxicity, QTc prolongation, reproductive toxicity and off-label use). http://www.mhra.gov.uk/home/groups/comms-ic/documents/drugsafetymessage/con428392.pdf [accessed 30 November 2014].
65. P. Plotkin, K. Patel, A. Uminski, and N. Marzella Telavancin (Vibativ), a new option for the treatment of Gram-positive infections P T 36 2011 127 138
66. M.W. Pletz, O. Burkhardt, and T. Welte Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? Comparison of pharmacology and clinical efficacy Eur J Med Res 15 2010 507 513
67. S. Deresinski Counterpoint: vancomycin and Staphylococcus aureus - an antibiotic enters obsolescence Clin Infect Dis 44 2007 1543 1548
68. M.J. Rybak, B.M. Lomaestro, J.C. Rotschafer, R.C. Moellering, W.A. Craig, and M. Billeter Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists Clin Infect Dis 49 2009 325 327
69. V.P. DiMondi, and K. Rafferty Review of continuous-infusion vancomycin Ann Pharmacother 47 2013 219 227
70. European Centre for Disease Prevention and Control Antimicrobial resistance surveillance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net), 2012 2013 ECDC Stockholm http://www.ecdc.europa.eu/en/publications/Publications/antimicrobial-resistance-surveillance-europe-2012.pdf [accessed 9 May 2014]
71. K.A. Rodvold, and K.W. McConeghy Methicillin-resistant Staphylococcus aureus therapy: past, present, and future Clin Infect Dis 58 2014 S20 S27
72. L. Vidaur, K. Planas, R. Sierra, G. Dimopoulos, A. Ramirez, and T. Lisboa Ventilator-associated pneumonia: impact of organisms on clinical resolution and medical resources utilization Chest 133 2008 625 632
73. A. Mazzariol, E. Kocsis, L. Bragagnolo, G. Pellizzer, M. Rassu, and G. Cornaglia Co-infection by two linezolid-resistant coagulase-negative staphylococci with two different resistance determinants Scand J Infect Dis 44 2012 978 981
74. A. Mazzariol, G. Lo Cascio, E. Kocsis, L. Maccacaro, R. Fontana, and G. Cornaglia Outbreak of linezolid-resistant Staphylococcus haemolyticus in an Italian intensive care unit Eur J Clin Microbiol Infect Dis 31 2012 523 527
75. M. Barros, R. Branquinho, F. Grosso, L. Peixe, and C. Novais Linezolid-resistant Staphylococcus epidermidis, Portugal, 2012 Emerg Infect Dis 20 2014 903 905